EcoDrugPlus

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSSVLG00005009832
Gene Symbol: PIK3R5
1 Cross references
255 Possible Orthologues:

Phospholipase A2 Group Iia

Ensembl ID : ENSSVLG00005002419
Gene Symbol: PLA2G2A
1 Cross references
172 Possible Orthologues:

Phospholipase A2 Group V

Ensembl ID : ENSSVLG00005002531
Gene Symbol: PLA2G5
1 Cross references
116 Possible Orthologues:

Phospholipase A2 Group Vii

Ensembl ID : ENSSVLG00005013209
Gene Symbol: PLA2G7
1 Cross references
203 Possible Orthologues:

Phospholipase A2 Group X

Ensembl ID : ENSSVLG00005025385
Gene Symbol: PLA2G10
1 Cross references
249 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSSVLG00005018429
Gene Symbol: PLAT
1 Cross references
204 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSSVLG00005011699
Gene Symbol: PTAFR
1 Cross references
224 Possible Orthologues:

Platelet Derived Growth Factor Receptor Alpha

Ensembl ID : ENSSVLG00005022004
Gene Symbol: PDGFRA
1 Cross references
204 Possible Orthologues:

Platelet Derived Growth Factor Receptor Beta

Ensembl ID : ENSSVLG00005007828
Gene Symbol: PDGFRB
1 Cross references
247 Possible Orthologues:

Platelet Derived Growth Factor Subunit B

Ensembl ID : ENSSVLG00005015796
Gene Symbol: PDGFB
1 Cross references
261 Possible Orthologues:

Polo Like Kinase 1

Ensembl ID : ENSSVLG00005025952
Gene Symbol: PLK1
1 Cross references
182 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 1

Ensembl ID : ENSSVLG00005010193
Gene Symbol: PARP1
1 Cross references
209 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).